Researchers running combination tablets frequently end up dividing them, taking half in the morning and half later, or quartering them across the day. The reasoning offered is usually that a divided dose smooths out the peak.
It does, for one of the two hormones. For the other it accomplishes nothing at all, and understanding which is which explains both why the practice persists and why a fixed-ratio tablet is an awkward format for anyone who needs it.
Research Grade · Discreet Worldwide Shipping
SRT4+T3-120 Slow Release T4+T3 (120/30mcg)
Splitting slow-release T3 as a single-hormone protocol is a different question with its own established patterns, covered in the slow-release T3 split-dosing analysis. This piece is specifically about combination tablets, where two hormones with very different kinetics are locked into one unit.
The Two Hormones Are Not on the Same Clock
Levothyroxine has a biological half-life on the order of a week. Liothyronine's is roughly 2.5 days, but its time to peak serum concentration after an immediate-release oral dose is about 2 to 4 hours.
Those two facts produce completely different daily profiles from the same tablet.
The T4 component accumulates into a large circulating pool and turns over slowly. A single daily dose contributes a small increment to that pool, and the resulting serum curve is essentially flat across twenty-four hours. There is no meaningful peak, and consequently nothing for a split to smooth.
The T3 component behaves nothing like this. It absorbs quickly, produces a distinct early rise, and then falls away from that peak as it distributes into tissue. That early rise is the thing researchers are trying to manage when they divide a tablet.
What Splitting Actually Achieves
Dividing a combination tablet in half and taking the halves twelve hours apart produces three effects, only one of which is the intended one.
On the T3 component: the intended effect. Half the T3 quantity produces a proportionally lower peak. Two smaller peaks replace one larger one, total daily exposure is unchanged, and the maximum serum concentration reached at any point in the day falls. For anyone whose difficulty is peak-correlated, this is the mechanism that helps.
On the T4 component: essentially nothing. Half a dose twice a day contributes the same daily quantity to a slowly turning-over pool as a whole dose once a day. Because the half-life is around a week, the pool does not perceptibly care how the day's increment arrived. The serum profile is unchanged in any way that matters.
On adherence and absorption: a cost. Two dosing events instead of one doubles the opportunities to miss a dose, and thyroid hormone absorption is sensitive to food, calcium, iron and several other co-administered substances, so a second daily dose is a second timing constraint to satisfy rather than a free operation.
The net position is that splitting a combination tablet buys a genuine improvement on one hormone, no change on the other, and a real practical cost across both.
Every Extra Dose Is an Extra Absorption Problem
The cost side of split dosing is usually described as inconvenience, which understates it. Thyroid hormone absorption is sensitive to a number of co-administered substances, so each additional dosing event is an additional window that has to be kept clear.
The interactions that recur in the literature and in practice fall into a few groups.
Separated by several hours. Calcium salts, iron preparations, and magnesium bind thyroid hormone in the gut and reduce absorption substantially. These are the ones that matter most, and they are common in exactly the population taking thyroid hormone.
Separated by a shorter interval. Food generally, and coffee in particular, reduce absorption to a degree that varies between individuals. Proton pump inhibitors and antacids alter gastric conditions in ways that affect dissolution.
Also relevant. Soy, high-fibre intake, and several binding resins.
The practical consequence for split dosing is arithmetical. A single daily dose requires one protected window. A twelve-hour split requires two. A three-times-daily pattern requires three, and those windows have to fit around meals, supplements and coffee across a whole day rather than being placed at the one point where the day is naturally empty.
For many people the morning dose is easy because waking provides a natural fasted window. The second and third doses are where split protocols actually fail, not because the pharmacology is wrong but because a mid-afternoon protected interval is difficult to sustain.
This is a genuine argument in favour of any approach that achieves peak reduction without adding dosing events, and it is separate from the pharmacological argument. Absorption timing is covered further in taking T3 with food or on an empty stomach.
The Structural Problem
Follow that logic one step further and it produces an uncomfortable conclusion about the format itself.
If the T3 needs dividing and the T4 does not, the ideal arrangement is levothyroxine once daily and liothyronine divided. A fixed-ratio combination tablet makes that arrangement impossible by construction, because the two hormones are physically bound in a fixed proportion within a single unit. Dividing one necessarily divides the other.
A fixed-ratio tablet is therefore structurally the wrong format for a protocol that requires split T3. It is an excellent format for a protocol that does not, and that is the honest boundary of what it is good for.
This is worth stating plainly because it cuts against combination tablets, which are otherwise a genuinely convenient format. Anyone who has arrived at splitting because of a peak-related problem has arrived at a point where the format is working against them, and the useful responses are to change the format rather than to divide harder.
There are three of those responses.
Separate components. Levothyroxine once daily and liothyronine divided as the protocol requires. This reproduces any ratio, allows the two hormones to be dosed on their own schedules, and costs the simplicity of a single tablet. The arithmetic is covered in the conversion reference.
An extended-release T3 component. If the problem is the early T3 peak, a formulation that releases T3 across a longer window addresses the same problem that splitting addresses, without division. Work on extended-absorption liothyronine, including a phase 1 human study of poly-zinc-liothyronine and translational work on sustained-release T3, has targeted exactly this. This is the subject of slow-release versus immediate-release combination therapy.
Accept the peak. Not every peak requires management. The case for splitting rests on a peak-correlated problem actually being present, and a substantial share of splitting is precautionary rather than responsive.
Should This Protocol Be Split At All?
Splitting is frequently adopted pre-emptively, on the general principle that smoother is better. That principle is reasonable but it is not free, and the costs above are real.
A more useful framing is that splitting addresses a specific class of problem, and is worth its costs when that class of problem is present.
Points toward splitting. Effects that appear reliably within a few hours of dosing and subside later in the day. A total T3 quantity high enough that a single administration produces a large peak. A protocol operating within a framework that specifies divided dosing structurally.
Points away from splitting. No peak-correlated pattern. Difficulty maintaining even one protected absorption window. A tablet strength that would require quartering to divide. Effects distributed evenly across the day, which suggests total exposure rather than peak height is the operative variable.
That last distinction is the one worth dwelling on, because it is diagnostic. Peak-correlated effects respond to redistributing the same daily quantity. Effects tied to total daily exposure do not, because splitting does not change total exposure at all. A researcher splitting in response to an exposure-related pattern will find that nothing improves, and may conclude that splitting failed when in fact it was addressing the wrong variable.
If dividing the dose changes nothing, the question worth asking is not how to divide it better but whether the total is the thing that needs attention.
The Fragment Accuracy Problem
Setting aside whether splitting is worth doing, there is a mechanical issue with doing it to a microgram-dosed tablet.
Pharmaceutical content uniformity is specified for the whole dosage unit. A manufacturer demonstrates that tablets contain the stated quantity within a tolerance; nothing in that specification extends to the halves or quarters a user creates afterward. The active ingredient is distributed through the tablet matrix, and while that distribution is designed to be even, "even enough that a whole tablet meets specification" is a weaker claim than "even enough that any fragment is proportional."
A score line assists a clean physical break. It does not certify the content of the resulting pieces.
The magnitude matters because of the doses involved. A combination tablet at 120/30 quartered into four pieces is being asked to deliver 7.5 mcg of T3 per fragment. A modest asymmetry in the break is a meaningful percentage of that quantity. The same asymmetry in a 500 mg tablet of something dosed in hundreds of milligrams would be irrelevant.
The practical implications are unglamorous but real: halves are considerably more reliable than quarters, a scored tablet is more reliable than an unscored one, alternating which half is taken first distributes any systematic bias across doses rather than concentrating it, and any protocol that requires a strength obtainable only by quartering is better served by a product manufactured at that strength.
If Splitting Is Still the Right Call
For researchers who have concluded that split dosing suits their protocol and are working with a combination tablet, the patterns in use are straightforward.
| Pattern | Structure | Typical rationale |
|---|---|---|
| 12 / 12 | Half on waking, half twelve hours later | The standard even split; lowest peak for a two-dose day |
| Two thirds / one third | Larger portion on waking | Keeps more of the day's T3 in waking hours |
| 8 / 8 / 8 | Three equal portions | Highest peak suppression; three fragments, greatest accuracy cost |
Two constraints apply across all of them.
Evening dosing interacts with sleep for some individuals, which is a recognised reason the second portion is often placed earlier rather than at a true twelve-hour interval. The timing considerations are examined in the morning versus evening dosing analysis.
And the assessment interval does not shorten because the dosing frequency increased. The T4 component still takes four to six weeks to reach steady state after any change, so a split pattern is evaluated on the same timeline as any other change to the protocol.
What the Evidence Establishes, and What It Does Not
Established. That levothyroxine and liothyronine have substantially different half-lives and serum profiles. That immediate-release liothyronine reaches peak serum concentration within a few hours of dosing. That dividing a dose reduces peak concentration while holding total daily exposure constant. That content uniformity specifications apply to whole dosage units.
Contested. Whether combination therapy is superior to monotherapy at all, which the consensus literature treats as unresolved, alongside a 2025 systematic review examining liothyronine safety.
Not established. That split dosing of a combination product produces better outcomes than single-daily dosing. That any particular split pattern is superior to another. That peak reduction translates into symptomatic benefit for a given individual. The pharmacokinetic effect of splitting is measurable; the outcome benefit is a hypothesis.
Frequently Asked Questions
Can I split a T4+T3 combination tablet?
Physically, usually yes, particularly if scored. Whether it is worthwhile depends on whether the problem being addressed is peak-related, because only the T3 component of the tablet has a peak that division affects.
Does splitting help the levothyroxine component?
No. Levothyroxine has a half-life of roughly a week and produces an essentially flat serum profile from once-daily dosing. Dividing it delivers the same daily quantity into the same slowly turning-over pool.
Why do people split combination tablets then?
Because of the liothyronine component, which peaks within about 2 to 4 hours of an immediate-release dose. Splitting halves the quantity per dose and therefore the peak, at the cost of dividing the T4 unnecessarily.
Is quartering a tablet accurate?
Less accurate than halving. Content uniformity is specified for whole tablets, not fragments, and at a 120/30 strength a quarter is being asked to deliver 7.5 mcg of T3, where a small asymmetry is a meaningful proportion of the dose.
Does a score line guarantee an even split?
No. A score line assists a clean physical break. It does not certify that the resulting pieces contain proportional quantities of active ingredient.
Is there a way to avoid splitting?
Two. Dose the hormones separately, so the T4 can be taken once daily while the T3 is divided, or use a formulation whose T3 component is extended-release, which addresses the same early peak without division.
How long before I can tell whether splitting helped?
The T3 effect is apparent within days. But if anything else about the dose changed at the same time, the T4 component still takes four to six weeks to reach steady state, so the full picture is not available earlier than that.
Does splitting change my total daily dose?
No. Dividing a dose redistributes the same daily quantity across more administrations. It changes the shape of the serum curve, not the area under it.
Closing Note
Splitting a combination tablet is a reasonable response to a real problem applied through a format that cannot accommodate it cleanly. The T3 component genuinely benefits. The T4 component is along for the ride, divided for no reason other than that it happens to be pressed into the same tablet.
That is not an argument against combination tablets. For a protocol that does not need split T3, a fixed-ratio single tablet is the simplest and most reliable way to take two hormones, and the case for it is strong. It is an argument for recognising when a protocol has outgrown the format, because continuing to quarter a microgram-dosed tablet in pursuit of a peak reduction that a different formulation would deliver intact is a lot of effort spent working around a constraint rather than removing it.
The SRT4+T3-120 slow release T4+T3 holds a 4:1 ratio at 120 mcg T4 with 30 mcg T3 while extending the release window of the T3 component, which addresses the peak that splitting is usually deployed against. For protocols requiring the two hormones on independent schedules, T4 levothyroxine at 100 mcg and the slow-release T3 range allow each to be dosed on its own timing.
All compounds discussed here are research chemicals supplied for laboratory research use only. Nothing in this article is medical advice, a treatment protocol, a dosing recommendation, or a recommendation for human or animal consumption. Thyroid hormone dosing carries genuine cardiovascular risk and the clinical evidence on combination therapy remains actively contested. Researchers should consult the primary literature cited below and appropriate qualified professionals.